The pharma will acquire Araris Biotech to gain access to three preclinical ADCs and a linking technology Araris claims is superior to existing platforms.
The pharma will acquire Araris Biotech to gain access to three preclinical ADCs and a linking technology Araris claims is superior to existing platforms.
